Intra-Cellular Therapies Inc. vice president Kimberly Vanover told BioWorld that the company "should have everything we need" to file an NDA for lumateperone, also known as ITI-007, in the middle of next year, and the company's shares (NASDAQ:ITCI) closed Wednesday at $14.39, up $3.12, or 27.7 percent, on word that the FDA found adequate the company's responses to a request for more information regarding toxicology experiments in dogs.